Academic Commons


Acquired Rifamycin Resistance with Twice-Weekly Treatment of HIV-related Tuberculosis

Burman, William; Benator, Debra; Vernon, Andrew; Khan, Awal; Jones, Brenda; Silva, Claudia; Lahart, Chris; Weis, Stephen; King, Barbara; Mangura, Bonita; Weiner, Marc; El-Sadr, Wafaa Mahmoud; Tuberculosis Trials Consortium

Rationale: Rifabutin was recommended in place of rifampin during treatment of HIV-related tuberculosis (TB) to facilitate concomitant potent antiretroviral therapy, but this approach has not been evaluated in a prospective study.

Objective: To evaluate the activity of intermittent rifabutin-based therapy.

Methods: Patients with culture-confirmed TB were treated under direct supervision with 2 mo of rifabutin, isoniazid, pyrazinamide, and ethambutol (given daily, thrice-weekly, or twice-weekly per the local tuberculosis control program), followed by 4 mo of twice-weekly rifabutin plus isoniazid.

Measurements: Culture-positive treatment failure or relapse.

Main Results: A total of 169 eligible patients were enrolled. Most had advanced HIV disease; the median CD4 cell count and HIV-RNA level were 90 cells/mm3 (interquartile range, 35–175) and 5.3 log10 copies/ml (interquartile range, 4.8–5.7), respectively. Nine (5.3%) patients had culture-positive treatment failure (n = 3) or relapse (n = 6). Eight of these nine (89%) cases had isolates with acquired rifamycin resistance. Treatment failure or relapse was associated with baseline CD4 lymphocyte count, being 12.3% (9/73; 95% confidence interval, 6.5–22.0%) among patients with CD4 < 100 cells/mm3 versus 0% (0/65; 95% confidence interval, 0.0–4.5%) among those with higher CD4 lymphocyte counts (p < 0.01). One hundred thirty-seven (81%) patients received antiretroviral therapy during TB treatment. Adverse events were common, but only two patients (1%) permanently discontinued study drugs.


Also Published In

American Journal of Respiratory and Critical Care Medicine

More About This Work

Academic Units
American Thoracic Society
Published Here
October 16, 2015
Academic Commons provides global access to research and scholarship produced at Columbia University, Barnard College, Teachers College, Union Theological Seminary and Jewish Theological Seminary. Academic Commons is managed by the Columbia University Libraries.